

Toshio Tanaka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2677251/publications.pdf>

Version: 2024-02-01

49
papers

7,577
citations

172457

29
h-index

206112

48
g-index

50
all docs

50
docs citations

50
times ranked

12799
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Anti-nucleocapsid antibodies enhance the production of IL-6 induced by SARS-CoV-2 N protein. <i>Scientific Reports</i> , 2022, 12, 8108. | 3.3 | 13 |
| 2 | Adipocytokine Profile Reveals Resistin Forming a Prognostic-Related Cytokine Network in the Acute Phase of Sepsis. <i>Shock</i> , 2021, 56, 718-726. | 2.1 | 17 |
| 3 | Reply to Cheng et al.: COVID-19 induces lower extent of cytokines, but damages vascular endothelium by IL-6 signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2105040118. | 7.1 | 0 |
| 4 | Prompt Reduction in CRP, IL-6, IFN- γ , IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 734838. | 2.6 | 13 |
| 5 | IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 22351-22356. | 7.1 | 215 |
| 6 | Targeting Interleukin-6 Signaling in Clinic. <i>Immunity</i> , 2019, 50, 1007-1023. | 14.3 | 570 |
| 7 | The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis. <i>Joint Bone Spine</i> , 2019, 86, 363-368. | 1.6 | 8 |
| 8 | Clinical Importance of a Cytokine Network in Major Burns. <i>Shock</i> , 2019, 51, 185-193. | 2.1 | 29 |
| 9 | Interleukin (IL-6) Immunotherapy. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028456. | 5.5 | 223 |
| 10 | The clinical importance of a cytokine network in the acute phase of sepsis. <i>Scientific Reports</i> , 2018, 8, 13995. | 3.3 | 114 |
| 11 | The role and therapeutic targeting of IL-6 in rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 535-551. | 3.0 | 166 |
| 12 | Clonal evolution and antigen recognition of anti-nuclear antibodies in acute systemic lupus erythematosus. <i>Scientific Reports</i> , 2017, 7, 16428. | 3.3 | 24 |
| 13 | IL-6 Superfamily. , 2017, , 573-586. | | 2 |
| 14 | Interleukin-6 Inhibition in Inflammatory Diseases: Results Achieved and Tasks to Accomplish. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, S20-S28. | 1.7 | 1 |
| 15 | Immunotherapeutic implications of IL-6 blockade for cytokine storm. <i>Immunotherapy</i> , 2016, 8, 959-970. | 2.0 | 521 |
| 16 | Regulation of IL-6 in Immunity and Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2016, 941, 79-88. | 1.6 | 135 |
| 17 | Therapeutic uses of anti-interleukin-6 receptor antibody. <i>International Immunology</i> , 2015, 27, 21-29. | 4.0 | 146 |
| 18 | Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic Implications. <i>Arthritis and Rheumatology</i> , 2015, 67, 1481-1490. | 5.6 | 79 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Interleukin 6 and Rheumatoid Arthritis. <i>BioMed Research International</i> , 2014, 2014, 1-12. | 1.9 | 149 |
| 20 | Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. <i>Biologics: Targets and Therapy</i> , 2014, 8, 141. | 3.2 | 45 |
| 21 | Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 344-354. | 3.4 | 118 |
| 22 | A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. <i>Seminars in Immunology</i> , 2014, 26, 88-96. | 5.6 | 144 |
| 23 | IL-6 in Inflammation, Immunity, and Disease. <i>Cold Spring Harbor Perspectives in Biology</i> , 2014, 6, a016295-a016295. | 5.5 | 2,943 |
| 24 | The Biology and Medical Implications of Interleukin-6. <i>Cancer Immunology Research</i> , 2014, 2, 288-294. | 3.4 | 283 |
| 25 | Flavonoids for Allergic Diseases: Present Evidence and Future Perspective. <i>Current Pharmaceutical Design</i> , 2014, 20, 879-885. | 1.9 | 30 |
| 26 | Can IL-6 blockade rectify imbalance between Tregs and Th17 cells?. <i>Immunotherapy</i> , 2013, 5, 695-697. | 2.0 | 21 |
| 27 | DNA Damage in Rheumatoid Arthritis: An Age-Dependent Increase in the Lipid Peroxidation-Derived DNA Adduct, Heptanone-Etheno-2-Deoxycytidine. <i>Autoimmune Diseases</i> , 2013, 2013, 1-8. | 0.6 | 9 |
| 28 | Interleukin-6; pathogenesis and treatment of autoimmune inflammatory diseases. <i>Inflammation and Regeneration</i> , 2013, 33, 054-065. | 3.7 | 13 |
| 29 | Immunotherapeutic implication of IL-6 blockade. <i>Immunotherapy</i> , 2012, 4, 87-105. | 2.0 | 35 |
| 30 | Anti-Interleukin-6 Receptor Antibody Therapy-Induced Retinopathy in a Patient with Rheumatoid Arthritis. <i>Case Reports in Rheumatology</i> , 2012, 2012, 1-4. | 0.6 | 7 |
| 31 | Tocilizumab for the Treatment of Rheumatoid Arthritis and Other Systemic Autoimmune Diseases: Current Perspectives and Future Directions. <i>International Journal of Rheumatology</i> , 2012, 2012, 1-14. | 1.6 | 40 |
| 32 | Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases. <i>International Journal of Biological Sciences</i> , 2012, 8, 1227-1236. | 6.4 | 200 |
| 33 | Therapeutic Targeting of the Interleukin-6 Receptor. <i>Annual Review of Pharmacology and Toxicology</i> , 2012, 52, 199-219. | 9.4 | 240 |
| 34 | Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. <i>Joint Bone Spine</i> , 2012, 79, 85-87. | 1.6 | 58 |
| 35 | A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. <i>Modern Rheumatology</i> , 2012, 22, 298-302. | 1.8 | 64 |
| 36 | Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. <i>Modern Rheumatology</i> , 2011, 21, 436-439. | 1.8 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. <i>Modern Rheumatology</i> , 2011, 21, 420-422. | 1.8 | 15 |
| 38 | Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab: Figure 1. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1164-1165. | 0.9 | 79 |
| 39 | Therapeutic effect of tocilizumab on two patients with polymyositis. <i>Rheumatology</i> , 2011, 50, 1344-1346. | 1.9 | 115 |
| 40 | Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. <i>Modern Rheumatology</i> , 2011, 21, 420-422. | 1.8 | 12 |
| 41 | Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. <i>Modern Rheumatology</i> , 2011, 21, 436-439. | 1.8 | 23 |
| 42 | The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. <i>Rheumatology</i> , 2010, 49, 2408-2412. | 1.9 | 177 |
| 43 | Tocilizumab for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 843-854. | 3.0 | 70 |
| 44 | Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica: Figure 1.. <i>Journal of Rheumatology</i> , 2010, 37, 1075-1076. | 2.0 | 55 |
| 45 | Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab. <i>Rheumatology</i> , 2010, 49, 824-826. | 1.9 | 21 |
| 46 | Minimal influence of tocilizumab on IFN- γ synthesis by tuberculosis antigens. <i>Modern Rheumatology</i> , 2010, 20, 130-133. | 1.8 | 25 |
| 47 | Minimal influence of tocilizumab on IFN- γ synthesis by tuberculosis antigens. <i>Modern Rheumatology</i> , 2010, 20, 130-133. | 1.8 | 20 |
| 48 | Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. <i>Arthritis and Rheumatism</i> , 2009, 61, 1762-1764. | 6.7 | 69 |
| 49 | Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. <i>Arthritis and Rheumatism</i> , 1999, 42, 1635-1643. | 6.7 | 195 |